Treatment for extreme drug-resistant tuberculosis wins US government approval
27 August 2019
The US Food and Drug Administration has approved a drug regimen to treat an extreme form of multi-drug-resistant tuberculosis (TB).
Nearly 90% of people infected with extensively drug-resistant (XDR) TB who took this treatment during a clinical trial recovered in 6 months. The average success rate for drug regimens currently used to treat XDR TB is around 34%
Further reading: Nature
Author(s): Amy Maxmen
Healthy Patients Smart Innovations
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Bangalore Bioinnovation Centre |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
 |
BD |
AMR NEWS
Every two weeks in your inbox
Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!